Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

p53 (368-386)

HAT substrate
 
BML-P198-2500 2.5 mg 173.00 USD
Do you need bulk/larger quantities?
 
Derived from the C-terminal regulatory domain of p53, this peptide comprises five lysines, including three preferentially acetylated by p300 (373, 381, 382). May be used as a substrate for assay of p300 and CBP HATs (Prod. No. BML-SE451 and BML-SE452).

Product Specification

Alternative Name:p300 & CBP substrate
 
Sequence:Ac-His-Leu-Lys-Ser-Lys-Lys-Gly-Gln-Ser-Thr-Ser-Arg-His-Lys-Lys-Leu-Met-Phe-Lys-CONH2
 
MW:2310.3
 
Formulation:Lyophilized.
 
Purity:≥95% (HPLC)
 
Appearance:Solid.
 
Solubility:Soluble in water.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 

Product Literature References

The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases: X.-J. Yang, et al.; Nucleic Acids Res. 32, 959 (2004), Abstract; Full Text
Histone acetyltransferases: S.Y. Roth, et al.; Annu. Rev. Biochem. 70, 81 (2001), Abstract;
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain: W. Gu & R.G. Roeder; Cell 90, 595 (1997), Abstract;

Related Products

p300 (catalytic domain) (human), (recombinant) 

Produced in E. coli. Catalytic domain (aa 1284-1673) of human p300. | Print as PDF
 
BML-SE451-0100 100 µg 404.00 USD
Do you need bulk/larger quantities?
 

CREB binding protein (catalytic domain) (human), (recombinant) 

Produced in E. coli. Catalytic domain (aa 1319-1710) of human CBP. | Print as PDF
 
BML-SE452-0100 100 µg 404.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,